• Mölnlycke
    Gamlestadsvägen 3C, Gothenburg, Sweden
    +46 (0)31 722 30 00
  • Magnus Nordberg

    Global Director Corporate Communications

    +46 31 722 34 98
    +46 739 41 29 98
  • Quotes

    Our aim is to ensure the healthcare professionals we work with in the UK have the tools needed to continue patient care, even in the uncertain times ahead. We see the UK distribution centre as essential to how we operate here in the UK as a way of minimising the impact that wider national and global situations may have on our product supply.
    Nick Rothwell, General Manager UK&I, Mölnlycke
    In addition to the immediate benefits with regards to efficient supply chain and reduced carbon footprint, the new UK distribution centre provides new and exciting opportunities for us to explore additional logistical services to benefit customers in the future.
    Colette Cadman, Logistics Services Director, Mölnlycke UK
    Adding oxygen therapy to our leading range of healing solutions for chronic wounds is a fundamental milestone for Mölnlycke in advancing wound care in this progressive and rapidly developing region
    Richard Twomey
    This exciting new technology will help reduce the incidence of serious infection and minimise the unnecessary use of antibiotics.
    Barry McBride, EVP R&D, Mölnlycke
    This is fully in line with where we want to be as a company, and M&J’s strong R&D capabilities combined with Mölnlycke’s end-product knowledge will help us further improve our competitive position within the advanced wound care industry.
    Richard Twomey, CEO
    We believe that the Mepilex Border Flex dressing may change the way wound care experts practice
    Randy Schwartz, Vice President of Marketing
    'Today, chronic wounds, such as foot ulcers, have a higher mortality rate than both breast cancer and prostate cancer and the real burden of ulcers is not yet fully known or understood. '
    Richard Twomey, CEO Mölnlycke
    Mӧlnlycke’s dedication to pressure injury prevention is an example of our shared commitment with the WOCN Society
    Rob Claypoole, U.S. President, Mölnlycke
    These market practices that allow extrapolation of evidence from one specific product to another similar type of product, even though the latter is not equivalent in material construction and design to the former, can put patients at risk.
    Richard Twomey, CEO
    Compared with the rigorous and thorough processes in place within the pharmaceutical industry for extrapolation of clinical evidence of efficacy from one product to another, parts of the medical devices industry is operating in a grey zone.
    Professor Amit Gefen
    Healthcare systems are under pressure to deliver better care to more people with a better value. Right now, healthcare is focused on outcomes. By focusing on prevention issues, you are able to help reduce some costs to the healthcare systems. Our solutions are designed to help reduce the risk of infection, hospital readmissions, and hospital acquired conditions. These are things that can lead to much higher costs, much higher patient suffering, and longer length of stay.
    Al Concemi, Vice President of Marketing – US Surgical Division
    Hibiclens isn’t just for the hospital – it also works in the home. That is why we continue to expand our retail availability to make it easier for consumers to buy Hibiclens. Because it bonds to your skin and has 24-hour protection, you’re able to resist the multitude of germs you come across in your daily lives.
    Al Concemi, Vice President of Marketing – US Surgical Division
    Mölnlycke is doing things right. Healthcare should always come first.
    J.L. Haber, Vice President of Programming for Worldwide Business
    Our solutions are true to Mölnlycke’s purpose of advance performance in healthcare across the world. When looking at the patient and caregiver experience, we aspire to equip both with solutions to achieve the best outcomes. This is why we care about prevention of Surgical Site Infections. Simply put, we know they are a significant issue impacting patient care and increasing health care costs and we want to be the best partner in making a positive difference in this space.
    Randy Schwartz, Vice President Wound Care Marketing US
    Continued caregiver and patient understanding is important to us and central to what we call having ‘Customer at Heart’. Combined with our gained expertise and advanced technologies, we’ve developed a portfolio of SSI bundle solutions for perioperative care. Mölnlycke truly believes that together we can make a difference. Everyone involved - the patient, health care provider, the care facility and our healthcare system overall- benefits when we are able to work together to reduce infection rates.
    Al Concemi, Vice President Surgical Marketing US
    Tissue Analytics is incredibly excited to work with Mölnlycke on this important initiative. We share the same passion to help patients.
    Kevin Keenahan, CEO of Tissue Analytics
    We are very excited to be part of AstraZeneca’s BioVentureHub, as it offers a unique opportunity for us to collaborate with AstraZeneca’s world-class scientists and benefit from their state-of-the-art facilities and infrastructure while developing new advanced wound care and surgical solutions for our customers.
    Richard Twomey, CEO Mölnlycke
    It’s fantastic that a well-established, global, medical solutions company like Mölnlycke wants to be part of our innovation experiment.
    Magnus Björsne, CEO for AstraZeneca’s BioVentureHub
    Our strong focus on product innovation and clinical evidence has continuously changed the way wounds are treated and prevented.
    Richard Twomey, CEO
    This reconfirms market confidence in Mölnlycke and our sound, long-term corporate strategy
    Stefan Fristedt, CFO
    Skin protectants are strategically important to our Prevention solution offer and the partnership with Rochal enables us to provide our customers with a complete solution within the pressure ulcer prevention area
    Richard Twomey, CEO, Mölnlycke Health Care
    It is our hope that the WUWHS consensus document will help clinicians and health care budget holders understand the role of dressings in PU prevention, as well as which dressings may protect against PU development and which patients may benefit.
    Professor Nick Santamaria
    The results of this research will contribute to developing a better understanding of the hidden costs of wound care and also, ultimately, to better patient care.
    Phil Cooper, President, Wound Care Division
    We finally have a product that really works; this is fantastic news for cancer patients.
    Dr. Patries Herst
    The BARRIER EasyWarm active self-warming blanket is a welcome addition to the tools available to healthcare professionals
    Professor Johan Raeder
    being granted FDA clearance gives us access to another important market, where we will launch during 2014
    Eric De Kesel
    Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top